Advanced Imaging to Evaluate Effects of Immunosuppression on Lung Fibrosis in Adults with Non-IPF Interstitial Lung Disease

What this Trial Is About

Researchers are investigating how immunosuppression treatment affects lung fibrosis in adults with non-idiopathic pulmonary fibrosis interstitial lung disease non-IPF ILD. This phase 2 study aims to assess changes in active collagen deposition and tissue injury by using advanced imaging techniques, including 68GaCBP8 positron emission tomography PET and dynamic contrast-enhanced magnetic resonance imaging DCE-MRI. Fifteen participants diagnosed with non-IPF ILD, who are starting immunosuppression treatment, will receive a single intravenous injection of 68GaCBP8 and gadoterate meglumine during imaging. They will undergo PET and DCE-MRI scans before treatment and again 12 weeks after treatment initiation to evaluate the effects of immunosuppression on lung fibrosis. Throughout the study, participants will be closely monitored with imaging assessments at baseline and at 12 weeks to measure changes in lung tissue characteristics. Researchers will evaluate primary outcomes such as changes in maximum standardized uptake value SUVmax25 and contrast wash-in rate over the lungs. Secondary outcomes include various imaging parameters assessing lung function. The study will continue until December 2028, with all safety and imaging data collected during the 12-week follow-up.

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis